This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Karam JA , Puligandla M , Flaherty KT , Uzzo RG , Matin SF , Pins MR , Wood CG , Kane C , Jewett MAS , Kim SE , Dutcher JP , DiPaola RS , Haas NB
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805
BJU Int. 2021 Sep 4
PMID: 34480522 URL: https://www.ncbi.nlm.nih.gov/pubmed/34480522
AbstractOBJECTIVES: To study the effects of adjuvant therapy in patients with sarcomatoid renal cell carcinoma (sRCC) enrolled in the randomised phase III clinical trial E2805. PATIENTS AND METHODS: The original trial (E2805) was a randomised, double-blinded phase III clinical trial comparing outcomes in 1943 patients with RCC accrued between 2006 and 2010 and treated with up to 1 year of adjuvant placebo, sunitinib, or sorafenib. The present study analyses the cohort of patients with sRCC that participated in E2805. RESULTS: A total of 171 patients (8.8%) had sarcomatoid features. Of these, 52 patients received sunitinib, 58 received sorafenib, and 61 received placebo. Most patients were pT3-4 (71.1%, 63.7%, and 70.5%, respectively); 17.3%, 19.0%, and 27.9% had pathologically positive lymph nodes; and 59.6%, 62.1%, and 62.3% of the patients were University of California Los Angeles (UCLA) Integrated Staging System (UISS) very-high risk. In 49% of patients with subsequent development of metastatic disease, recurrence occurred in the lung, followed by 30% in the lymph nodes, and 13% in the liver. There was a high local recurrence rate in the renal bed (16%, 29%, and 18%, respectively). The 5-year disease-free survival (DFS) rates were 33.6%, 36.0%, and 27.8%, for sunitinib, sorafenib and placebo, respectively (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.45-1.20 for sunitinib vs placebo, and HR 0.82, 95% CI 0.53-1.28 for sorafenib vs placebo). CONCLUSIONS: Adjuvant therapy with sunitinib or sorafenib did not show an improvement in DFS or OS in patients with sRCC.
Notes1464-410x Karam, Jose A Orcid: 0000-0001-7697-9591 Puligandla, Maneka Flaherty, Keith T Uzzo, Robert G Matin, Surena F Orcid: 0000-0003-1638-1445 Pins, Michael R Wood, Christopher G Orcid: 0000-0003-3450-8809 Kane, Christopher Jewett, Michael A S Kim, Se Eun Dutcher, Janice P DiPaola, Robert S Haas, Naomi B U10CA180820/National Cancer Institute/ National Institutes of Health/ U10CA180794/National Cancer Institute/ National Institutes of Health/ U10CA180888/National Cancer Institute/ National Institutes of Health/ U10CA180821/National Cancer Institute/ National Institutes of Health/ U10CA180863/National Cancer Institute/ National Institutes of Health/ #704970/Canadian Cancer Society/ UG1CA233239/Canadian Cancer Society/ UG1CA233180/Canadian Cancer Society/ Journal Article England BJU Int. 2021 Sep 4. doi: 10.1111/bju.15587.